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Here we report a new family of cyclic antimicrobial peptides (CAMPs) targeting MDR strains of
Pseudomonas aeruginosa. These CAMPs are cyclized via a xylene double thioether bridge connecting
two cysteines placed at the ends of a linear amphiphilic alternating D,L-sequence composed of lysines
and tryptophans. Investigations by transmission electron microscopy (TEM), dynamic light scattering and
atomic force microscopy (AFM) suggest that these peptide macrocycles interact with the membrane to
form lipid–peptide aggregates. Amphiphilic conformations compatible with membrane disruption are
observed in high resolution X-ray crystal structures of fucosylated derivatives in complex with lectin
LecB. The potential for optimization is highlighted by N-methylation of backbone amides leading to
derivatives with similar antimicrobial activity but lower hemolysis.Introduction
There is an urgent need to develop new antibiotics to control
multidrug resistant (MDR) bacteria. Here we report the design
of new cyclic antimicrobial peptides (CAMPs, e.g. RH11,
Scheme 1) against the Gram-negative opportunistic bacterium
Pseudomonas aeruginosa, which represents a major cause of life
threatening infections in hospitals today.1,2 CAMPs are exam-
ples of peptidemacrocycles, one of themost important family of
pharmacologically active natural products at sizes beyond small
molecules.3–6 Peptide macrocycles are attractive because they
can be easily prepared by ordered oligomerization of a-amino
acids or related building blocks such as N-alkyl glycines7,8 using
solid-phase peptide synthesis followed by cyclization,9 and their
macrocyclic structure allows an organized positioning of phar-
macophores favoring biological activity.
Notable CAMPs against P. aeruginosa include the natural
product polymyxin, currently a last resort antibiotic against, University of Bern, Freiestrasse 3, 3012
d@dcb.unibe.ch
Medicine, University of Geneva, Service of
eneva, Geneva, Switzerland
y of Solid Surfaces, College of Chemistry
ity, Xiamen 361005, China
(ESI) available: Compounds analytical
tails of AFM, and list of structures as
work.MDR Gram-negative bacteria acting primarily by membrane
disruption but against which resistance is appearing,10,11 the
natural disulde bridged cyclic dodecapeptide bactenecin andScheme 1 Synthesis of RH11. Conditions: (a) SPPS: Fmoc depro-
tection: piperidine/NMP 1 : 4 (v/v), 20 min; amino acid coupling: 3 eq.
Fmoc-aa-OH, 3 eq. PyBOP, 5 eq. DIEA in NMP, 2–4 hours; (b)
cleavage: TFA/TIS/H2O (95/4/1/); (c) cyclization: KI (20 eq.) DIPEA (5
eq.) a,a0-dichloro-p-xylene (3 eq.) in CH3CN/H2O (1 : 1, v/v), RT, 1–2
hours under Argon.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlineanalogs,12 and POL7080, a recently developed synthetic CAMP
blocking P. aeruginosa membrane assembly via the lipid trans-
port protein lptD.13 Synthetic polymyxin analogs with fewer
positive charges were recently shown to have reduced toxicity
but also weaker antimicrobial activity.14,15
Here we decided to take a fresh start and search for entirely
new CAMPs, keeping focused on membrane disruption because
this represents the favored mechanism of action of CAMPs and
their parent linear antimicrobial peptides (AMPs).16–20 In
contrast to targeted protein binding by peptide macrocycles,
which requires aﬃnity selection from very large genetically
encoded combinatorial libraries,21,22 membrane disruptive
activities can be approached by design. Indeed, amphiphilic
structures combining cationic residues potentially binding to
the anionic phosphate groups of phospholipids with hydro-
phobic residues facilitating membrane penetration oen
disrupt biological membranes.
Amphiphilic CAMP structures can be observed directly in the
crystal structures of the cyclic antimicrobial decapeptides
Gramicidin S forming an intramolecular b-sheet23–25 and Tyro-
cidin A existing as a hydrogen-bonded amphiphilic dimer in the
crystal.26 Many CAMPs have been discovered by modifying
natural products such as Gramicidin S27–29 and bactenecin,12 as
well as by cyclizing naturally occurring linear amphiphilic
antimicrobial hexa- to octa-peptides featuring arginine–trypto-
phan as cationic–hydrophobic pair.30–33 Further examples of
amphiphilic designs include cyclic peptoids with alternating
aromatic and primary alkylamine side chains,34,35 and cyclic
hexa- and octa-peptides featuring an alternating D,L-architecture
forming supramolecular tubular aggregates.36–39 Strikingly
however most of these CAMPs were developed against Gram-
positive strains such as Staphylococcus aureus and some Gram-
negative strains such as E. coli, but apart from bactenecin,
polymyxin and POL7080 discussed above, only very few of them
were reported to be active against P. aeruginosa.
In our attempt to discover new CAMPs against P. aeruginosa,
we selected peptide macrocycles cyclized via a xylene double
thioether bridge connecting a pair of cysteine residues placed at
both ends of a linear sequence (Scheme 1). This xylene linker
allows for a high-yielding cyclization40 and has been reported
for synthetic epitope design41,42 and genetically encoded
libraries,43 but has not been used previously in CAMPs. We
adopted Ghadiri's alternating D,L-sequence design36–39 to
promote aggregation and serum stability and used lysine/
tryptophan as cationic/hydrophobic residue pair, an unprece-
dented combination for CAMPs.
As detailed below, reaching a size of 11 residues was essen-
tial to confer activity against P. aeruginosa including MDR
clinical isolates. The optimal CAMP RH11 displays good
stability in serum, moderate hemolysis, and the hallmarks of
membrane disruptive activity. Imaging by transmission elec-
tron microscopy (TEM) and atomic force microscopy (AFM)
shows that RH11 disrupts the bacterial membrane to form
doughnut shaped structures suggesting the formation of lipid–
peptide aggregates. Its amphiphilic structure is furthermore
supported by high resolution X-ray crystal structures of fuco-
sylated derivatives of close analogs in complex with lectin LecBThis journal is © The Royal Society of Chemistry 2017of P. aeruginosa,44 a method which we have recently found to
provide access to structural information on molecules other-
wise diﬃcult to crystallize.45,46 The structure also shows that
backbone amides are not engaging in critical hydrogen bonds,
leading to the exploration of backbone N-methylation as a route
for property improvements.
Results and discussion
Design, synthesis and optimization
To build our cyclic peptides we focused on sequences contain-
ing an approximately even ratio of hydrophobic and cationic
residues since this composition generally favors antimicrobial
activity.16–20 As components of the amphiphilic sequence we
selected tryptophan as hydrophobic residue because it is most
oen used in designed synthetic AMPs including CAMPs.30–33
On the other hand we chose lysine as cationic amino acid since
it occurs most frequently in natural AMPs, and because lysine
cationic side chains had served us well in obtaining antimi-
crobial peptide dendrimers and bicyclic peptides with high
activities against P. aeruginosa.47–49 Despite of the fact that
arginine is very prevalent in synthetic membrane active
peptides, we did not want to use this residue because it also
promotes cell penetration in eukaryotic cells and hemo-
lysis.32,50–54 Finally we expected that the xylene bridge would play
the role of a hydrophobic residue enhancing membrane inter-
actions and possibly aggregation and might therefore positively
contribute to antimicrobial eﬀects.
To probe the size requirement of our amphiphilic sequence
design we initially prepared a small series of CAMPs between 6
and 12 residues (RH1–RH7, Table 1). We tested their possible
antimicrobial activity by determining minimal inhibitory
concentrations (MIC) in a broth dilution assay against our
target Gram-negative bacterium P. aeruginosa PAO1, as well as
against Bacillus subtilis BR151, a Gram-positive strain generally
sensitive to membrane disruptive compounds. The shorter
sequences RH1–RH5 showed activity against B. Subtilis BR151
but were inactive against PAO1. By contrast the larger cyclic
undecapeptide RH6 showed signicant activity against PAO1
(MIC ¼ 16 mg mL1), while retaining a robust activity against B.
subtilis (MIC ¼ 2 mg mL1). Activity was preserved upon
replacement of the para-xylene bridge withmeta- or ortho-xylene
bridges in RH6m and RH6o, but was strongly decreased in the
disulde-bridged analog RH6ss, indicating that the xylene
bridge was necessary for activity, presumably due to its contri-
bution to hydrophobicity. Activity was slightly reduced with the
phenylalanine analog RH8 and lost with the leucine analog
RH9, showing that tryptophan was the optimal hydrophobic
residue for RH6. Activity was preserved when placing the p-
xylene bridge at the center of the penta-lysine sequence in
RH10, and slightly increased when placing the bridge at the
center of the tetra-tryptophan sequence in RH11, which
simultaneously reduced its hemolytic eﬀect.
An optimum in sequence design was apparently reached with
RH11. Sequence amphiphilicity was essential for its activity as
indicated by the almost complete loss of activity in analog RH12
with alternating tryptophan and lysine residues. RH12 was nonChem. Sci., 2017, 8, 7464–7475 | 7465
Table 1 Activity of CAMPs against Gram-negative (P. aeruginosa PAO1) and Gram-positive (B. subtilis BR151) bacterial strains
Peptide Hyd. Pos.a Linear sequenceb MICc PA01 MICc BR151 MHCd
Pmx 4 5 Polymyxin B 0.5 16 >2000
RH1 3 4 cWkKkC >64 64 1000
RH2 4 4 CwWkKkC 64 8 125
RH3 4 5 cWwKkKkC 64 16 500
RH4 5 5 CwWwKkKkC 64 4 125
RH5 5 6 CwWwKkKkKC >64 2 1000
RH6 6 6 CwWwWkKkKkC 16 2 31
RH7 6 7 cWwWwKkKkKkC 32 2 31
RH6m 6 6 CwWwWkKkKkCe 16 2 31
RH6o 6 6 CwWwWkKkKkCf 16 2 31
RH6ss 6 6 CwWwWkKkKkCg 64 8 n.d.
RH8 6 6 CfFfFkKkKkC 32 2 500
RH9 6 6 ClLlLkKkKkC >64 16 >2000
RH10 6 6 CkKkWwWwKkC 16 1 250
RH11 6 6 CwWkKkKkWwC 8 1 125
dRH11 6 6 cWwKkKkKwWc 8 1 n.d.
RH11m 6 6 CwWkKkKkWwCe 8 1 n.d.
RH11o 6 6 CwWkKkKkWwCf 8 1 n.d.
RH12 6 6 CkWkWkWkWkC >64 16 1000
RH13 7 6 CWwKkKkKwWwC 8 1 125
dRH13 7 6 cwWkKkKkWwWc 8 1 n.d.
RH14 7 5 CwWkKkKwWwC 32 2 8
RH15 5 7 CwKkKkKkWwC 64 2 250
RH16 6 6 ClLkKkKkLlC 64 4 >2000
RH17 6 6 CWWKKKKKWWC 16 1 250
RH18 6 6 CMewWkKkKkWMewCh 16 4 8
RH19 6 6 CwMeWkKkKkWMewCh 16 4 1000
RH20 6 6 CwWMekKkKMekWwCh 16 2 1000
a Hyd. ¼ number of hydrophobic residues including cysteines, Pos. ¼ positive charges (from lysine side chains and N-terminus). b Sequences are
cyclized with a,a0-dichloro-para-xylene. Upper case letters are used for L-amino acids and lower case letters for D-amino acids, the C-terminal
cysteine is carboxamide (CONH2) from Rink amide synthesis.
c The MIC (minimal inhibitory concentration) in mg mL1 was measured by 1/2
serial dilutions in Mu¨ller–Hinton (MH) broth in 96 well plates aer incubation for 16–18 hours at 37 C. The MIC values were measured in
independent triplicates with at least two experiments giving the same value. d MHC ¼ minimal hemolytic concentration in mg mL1, measured
by 1/2 serial dilutions on human red blood cells (HRBCs) in 96 well plates. The MHC values were measured in duplicates giving the same value.
n.d. ¼ not determined. e Cyclized with a,a0-dichloro-meta-xylene. f Cyclized with a,a0-dichloro-ortho-xylene. g Cyclized with disulde bridge. h Me
for N-methylation of the peptide bond.
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View Article Onlinehemolytic, indicating that sequence amphiphilicity caused the
hemolytic eﬀect. Extending the hydrophobic part by one trypto-
phan preserved antimicrobial activity in RH13, while activity
decreased when perturbing the lysine/tryptophan ratio in RH14 or
RH15. Exchanging the four tryptophans against less hydrophobic
leucines in RH16 also reduced antimicrobial activity, and
completely abolished hemolysis. Interestingly RH17 containing
only L-amino acids was as active as RH11, showing that the
alternating D,L-architecture was not necessary for activity. Never-
theless RH17 was unstable in serum while RH11 was resistant to
degradation, implying that the D,L-sequence design was required
for stability (Fig. 1A). Interestingly the most active CAMPs RH11
and RH13 were comparably active as their enantiomers dRH11
and dRH13.Activity against MDR strains
The three most active CAMPs RH6, RH11 and RH13 were
further evaluated against clinical respiratory tract isolates of
P. aeruginosa. The isolates ZEM9A, ZEM1A, PEJ2.6, and PEJ9.1
(provided by CHUV, Lausanne, Switzerland) were resistant
against two to three diﬀerent classes of antibiotics, including b-7466 | Chem. Sci., 2017, 8, 7464–7475lactams (cephalosporins, carbapenems), aminoglycosides
(amikacin, gentamicin, tobramycin), or quinolones (nor-
oxacin, ciprooxacin). Because our CAMPs were quite active
on the Gram-positive test strain B. subtilis, we also included the
Gram-positive pathogens S. aureus Newman (methicillin sensi-
tive) and S. aureus COL (methicillin-resistant), against which
many CAMPs are active.
Both optimized CAMPs RH11 and RH13 showed good activi-
ties (MIC# 16 mg mL1) against three of the four MDR strains of
P. aeruginosa, although they weremuch less active than polymyxin
B. Both compounds were also slightly active against S. aureus
strains, further illustrating a signicant activity against Gram-
positive strains contrasting with polymyxin B, which is specic
for Gram-negative bacteria. RH11 and RH13 also showed
moderate activity against Acinetobacter baumannii, but not against
Escherichia coli or Klebsiella pneumoniae (Table 2).Membrane disruptive eﬀects
RH11 behaved as a typical membrane disruptive compound.
DNA was rapidly released from bacteria upon treatment with
the peptide as measured by the SYTOX dye, an eﬀect clearlyThis journal is © The Royal Society of Chemistry 2017
Fig. 1 (A) D,L-Peptides RH6 (red), RH11 (blue) and all L-peptide RH17
(black) (at c ¼ 685 mg mL1) were incubated in human serum over 24
hours and remaining peptide was quantiﬁed by LC/MS. (B) PAO1
membrane integrity was measured by monitoring DNA release using
the SYTOX dye and ﬂuorescence spectroscopy. PAO1 cells in minimal
salts medium were treated with SYTOX and each of the antibiotics/
AMPs (added at time ¼ 0) at a concentration of 4  MIC. The ﬂuo-
rescence change is shown during 60 min. (C) TEM images showing
morphology of PAO1 cells incubated for 60 min without compound
(left), or with 10MIC polymyxin B (center) and 10MIC RH11 (right).
(D) Particle size distribution observed by DLS in solutions of 100 mg
mL1 E. coli LPS without or with antibiotic compound at 100 mg mL1.
Each sample was measured in triplicate and the experiments were
repeated three times.
Table 2 Activity on clinical strains of P. aeruginosa and S. aureusa
RH6 RH11 RH13
Polymyxin
B
ZEM1.A 32 16–32 8–16 0.125
ZEM9.A 8 8–16 8 4
PEJ2.6 16–32 4–8 8–16 0.5
PEJ9.1 >64 64 32 0.5
S. aureus Newman (MSSA) 64 16–32 32 >64
S. aureus COL (MRSA) 32–64 16–32 32 >64
A. baumannii 19606 n.d. 16 16 0.125
E. coli (W3110) n.d. 32 64 0.125
K. pneumoniae s. n.d. >64 >64 1
a MICs were determined by serial two-fold dilutions in Mueller–Hinton
(MH) broth in 96 well plates aer incubation for 16–18 hours at 37 C.
Experiments were performed in triplicates with at least two independent
experiments giving the same value. Resistance proles in Table S1.†
MSSA: methicillin-sensitive S. aureus, MRSA: methicillin-resistant S.
aureus.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinelinked to bacterial killing since the inactive analog RH12 did
not induce DNA release (Fig. 1B).13,55 Furthermore RH11
induced uorescein release from anionic phosphatidylglycerol
vesicles mimicking the bacterial membrane (Fig. S1†). Trans-
mission electronmicroscopy (TEM) images of P. aeruginosa cells
exposed to RH11 were comparable to those obtained with
polymyxin B,56 and showed the formation of membrane
protrusions that suggest membrane disruption (Fig. 1C and
S2†). The size of lipopolysaccharide (LPS) aggregates measured
by dynamic light scattering (DLS) increased in the presence of
RH11 as for polymyxin B, but were unaltered by tobramycin,
a non-membrane active antibiotic, suggesting that the protru-
sions observed by TEM represented LPS–peptide aggregates
(Fig. 1D and S3†).
Atomic force microscopy
The TEM and DLS data suggested that RH11 interacts with the
bacterial membrane to form lipid–peptide aggregates. To gain
an additional insight into the action of RH11 on the bacterial
membrane, we performed an atomic force microscopy (AFM)
study. Unfortunately, no satisfactory AFM images could be ob-
tained using P. aeruginosa. However, treatment of B. subtilis
with RH11 induced the formation of highly homogeneous
doughnut-like structures with a diameter around 80 nm and
height around 0.8 nm (Fig. 2B–D). Control experiments showed
that these doughnut-like structures were not formed with either
B. subtilis or RH11 alone (Fig. S4†). Similar doughnut-like
structures with 85–90 nm of diameter and 0.6 nm of height
were also observed upon treatment of phosphatidylglycerol
lipid vesicles with RH11 (Fig. 2E and F). Such regular nano-
structures were not observed previously in AFM studies of
bacterial and lipid vesicles with AMPs such as indolicidin,57
polymyxin B,58 magainin 2 (ref. 59) or endotoxin-binding Sushi
peptides.60 On the other hand similar doughnut-like structures
have been reported previously in AFM studies of designed
amphiphilic peptide based surfactants in the absence of any
membrane,61,62 however the objects were approximately double
in size. In our studies the dimensions of the doughnut-like
structures depend on the membrane, which suggests that they
represent aggregates of membrane lipids and RH11. We
propose that these structures are comparable to the protrusions
observed by TEM which have a comparable size of 50–100 nm
(Fig. 1C), and are formed by aggregation of the peptide at the
bacterial membrane or lipid vesicle surface followed by
detachment when a critical size has been reached, leading to
membrane lysis and cell death in the case of bacteria (Fig. S5†).
X-ray crystallography
In view of the above experimental evidences for membrane
disruptive eﬀects by RH11 we next determined its X-ray crystal
structure to see if its amphiphilic character was comparable to
that reported in the X-ray crystal structures of typical membrane
disruptive CAMPs such as Gramicidin S23 and Tyrocidin A.26
Since our attempts to crystallize RH11 directly were unsuc-
cessful, we prepared analogs of RH11 extended with an a-L-c-
fucosylacetyl group at the N-terminus of the peptide in view ofChem. Sci., 2017, 8, 7464–7475 | 7467
Fig. 2 AFM image of B. subtilis cells on mica surface with or without
treatment with CAMP RH11 at 4  MIC (see methods for details). (A)
Control cells without treatment; (B) cells after treatment with RH11,
the AFM image shows doughnut-like structures around the bacteria.
(C) Focus on doughnut-like structures observed with B. subtilis treated
with RH11. (D) zoom image of (C). (E) AFM image of phosphatidylgly-
cerol lipid vesicles treated with RH11. (F) zoom image of phosphati-
dylglycerol lipid vesicles with RH11.
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View Article Onlineobtaining the CAMP structures as complexes with the
fucose specic P. aeruginosa lectin LecB, which crystallizes
readily.44–46,63 We prepared fucosylated derivatives for RH11, its
enantiomer dRH11, as well as for the o-xylene and m-xylene
analogs RH11o and RH11m, which were as active as RH11 itself,
and for their respective enantiomers dRH11o and dRH11m. We
screened crystallization conditions in all six cases either by co-
crystallization of the ligands with LecB or by soaking preformed
LecB crystals with the ligands.
In the three cases of cyclic peptide–LecB complexes for which
we obtained well-resolved data, which were all obtained by co-
crystallization, the crystal symmetry resulted in four non-
equivalent LecB monomers and the corresponding complexed
fucosyl ligands in each LecB tetramer. Each of the four binding
sites was occupied by a fucosylated ligand (Table S2†). Electron
densities allowing structure determination of the cyclic peptide
portion were observed for three out of four binding sites in the
case of FdRH11o (the fucosylated enantiomer of RH11o, 5NF0,
1.27 A˚ resolution, Fig. 3a–e, S6a and b†), as well as for a single
LecB binding site in the cases of FRH11o (fucosylated RH11o,
5NEY, 1.54 A˚ resolution, Fig. 3f and S6c†) and FdRH11m
(fucosylated enantiomer of RH11m, 5NES, 1.60 A˚ resolution,7468 | Chem. Sci., 2017, 8, 7464–7475Fig. 3 and S6d†). For all structures the peptide backbone as well
as a large part of the amino acid side chains were well ordered,
however side chains had very diﬀerent B-factors in the diﬀerent
structures. The side chains of FdRH11o were completely
ordered in all three conformers with very low B-factors, with
almost every atom perfectly dened. By contrast FRH11o had
higher side chain B-factors, and only its tryptophan side chains
were ordered. In the case of FdRH11m the tryptophan side
chains and the side chain of lys8 were ordered because it was
immobilized by a 3.2 A˚ hydrogen bridge to the fucosyl group,
however the other lysine side chains had high B-factors and
were disordered.
Close analysis of each structure showed that cyclic peptides
engaged in several backbone hydrogen bonds, several of them
water-bridged (Fig. 3d–f and 2h). Dihedral angles resided in
allowed regions of the Ramachandran plots except for two cases
corresponding to poorly resolved portions of the peptide backbone
with poor electron density indicating exibility (Fig. 3i and j).
An overlay of the a-carbon backbone of the three structures of
FdRH11o and the single structure of FRH11o provided direct
structural evidence that this CAMP could adopt a variety of
conformations, suggesting that these cyclic peptides were con-
formationally quite exible, somewhat in contrast to the rather
rigid structures observed with Gramicidin S in crystals23 or by
NMR in membrane environment,64 or in the X-ray structure of the
Tyrocidin A dimer (Fig. 3g).26 Nevertheless in all conformations
observed in the X-ray structures our cyclic peptides adopted an
amphiphilic structure grouping the hydrophobic xylene bridge
and the tryptophan side chains on one side and the cationic lysine
side chains on the other, in agreement with the original sequence
design. Because there were almost no contacts between the cylic
peptides and LecB apart from the fucose anchor we believe that
these conformations are comparable to the conformation for the
free peptides, and therefore support the membrane disruptive
mechanism of action of RH11.N-Methylation of backbone amides
The formation of intramolecular backbone hydrogen bonds
including water-bridges observed in the crystal structures above
suggested that our CAMPs were not preorganized for nanotube
forming intermolecular backbone H-bonds despite of their
alternating D,L-sequence inspired by Ghadiri's cyclic peptides. To
test whether backbone H-bonds had any inuence on the activity
of RH11 we prepared three analogs RH18, RH19 and RH20, each
featuring a diﬀerent pair of N-methylated residues, using the 2-
nitrobenzene sulfonamide method for N-methylation of the
selected residues during SPPS.65 All three derivatives retained
most of the antimicrobial activity of RH11 despite of each having
two blocked N-methyl group unable to act as backbone H-bond
donors, conrming that activity was independent of a precise
pattern of backbone amide bonds (Table 1).
Interestingly, N-methylation inuenced hemolytic activity,
with RH18 showing stronger hemolysis than RH11 and RH19/
RH20 showing much weaker hemolysis than RH11. Although N-
methylation is a standard backbone modication to tune the
pharmacological properties of peptides,66 modulation ofThis journal is © The Royal Society of Chemistry 2017
Fig. 3 X-ray crystal structure of fucosylated analogs of RH11 in complex with lectin LecB. (a) Overview of the FdRH11o–LecB complex showing 2
symmetric copies of the LecB tetramer. The protein is shown as ribbons and the cyclic peptides in stick model, each symmetry non-equivalent
LecB monomer and its bound ligand are shown in the same color. The orange (FdRH11o-1), green (FdRH11o-2), and blue (FdRH11o-3)
monomers reveal a fully resolved bound ligand. (b) Detail of the FdRH11o-1 shown with blue dashed cloud density. (c) Cyclic peptide portion of
FdRH11o-1 in stick model with cationic lysine side chains in blue and hydrophobic residues (Trp and the xylene bridge) in ruby, showing one
water-bridged hydrogen bond and four backbone H-bonds forming an improper short b-sheet like structure. The chosen cut-oﬀ distance for
hydrogen bridges is 3.2 A˚. (d) Cyclic peptide portion of FdRH11o-2 in stick model with two backbone H-bonds and two water-bridged backbone
H-bonds. (e) Cyclic peptide portion of FdRH11o-3 in stick model, with backbone H-bonds connected via four crystallographic water molecules,
one backbone H-bond involving the C-terminus, and a backbone-to-lysine side chain H-bond. (f) Cyclic peptide portion of FRH11o in stick
model as observed in its LecB complex, with missing side-chains modeled in, showing two backbone H-bonds. (g) Overlay of a-carbon
backbone observed in the three occupied sites of the FdRH11o–LecB complex (orange, green and blue) and the single occupied site of FRH11o–
LecB complex (magenta). (h) Cyclic peptide in stick model as observed in the FdRH11m–LecB complex, with missing side-chains modeled in,
showing one water bridged backbone H-bond and one H-bond between an indole NH and a backbone carbonyl. (i) Ramachandran plot for all L-
residue dihedrals in the cyclic peptides. (j) Ramachandran plot for all D-residue dihedrals in the cyclic peptides. In both plots the allowed regions
are shown in red and yellow. See also Table S2 and Fig. S6.†
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View Article Onlinehemolytic properties by backbone N-methylation has not been
reported previously for CAMPs and suggests a route for ne-
tuning the properties of RH11.
Conclusion
In summary, investigating amphiphilic peptides with an alter-
nating D,L-architecture cyclized by a xylene double thioether
bridge led to the discovery of RH11 as a potent CAMP with
activity against P. aeruginosa including MDR clinical isolates,
good serum stability and moderate hemolysis. A suﬃcient ringThis journal is © The Royal Society of Chemistry 2017size was essential in obtaining activity against P. aeruginosa.
RH11 displayed membrane disruptive activity evidenced by DLS
and TEM experiments. AFM images of bacteria exposed to RH11
showed that the interaction of RH11 with the membrane led to
the formation of doughnut shaped structures tentatively
attributed to supramolecular lipid–peptide aggregates. The
amphiphilic nature of RH11 was conrmed by high resolution
X-ray crystal structures of fucosylated analogs in complex with
lectin LecB, which showed that these CAMPs can adopt a variety
of conformations involving intramolecular and partly
water-bridged backbone H-bonds, but are not preorganized forChem. Sci., 2017, 8, 7464–7475 | 7469
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View Article Onlineintermolecular aggregation. N-Methylation of backbone amides
in RH11 led to derivatives with similar potency but reduced
hemolysis, suggesting a route for further optimization.
The structures of RH11 and analogs diﬀer considerably from
other CAMPs from the literature discussed in the introduction.
In addition to the use of a xylene double thioether bridge, our
choice of lysine as the only cationic residue was somewhat
special because CAMPs usually contain combinations also
involving arginine, ornithine and diaminobutyric acid. Our
CAMPs also stand out by the unique combination of lysine with
tryptophan as the only hydrophobic residue, leading to an
unusually high fraction of aromatic groups (Fig. S7A†). High
aromaticity is otherwise reported only in Arg/Trp cyclic
peptides, while all other CAMPs also feature aliphatic hydro-
phobic residues (Leu, Pro, Val). Furthermore, with 120 heavy
atoms and 6 positive charges, RH11 is among the largest and
most highly charged CAMPs (Fig. S7B†). Although this property
is shared with the P. aeruginosa specic CAMP POL7080 and its
analogs as well as BacR, an analog of bactenecin optimized for
P. aeruginosa,12 polymyxin B is signicantly smaller and has only
5 positive charges. In addition to N-methylation, optimization
of RH11 might therefore also consider non-aromatic hydro-
phobic groups as well as size and charge reduction to address
not only MDR antimicrobial activity but also toxicity issues
beyond hemolysis and eventually in vivo eﬀects.Experimental
General
All reagents were purchased from Sigma Aldrich and Fluka, TCI
Europe, Advanced ChemTech and Iris Biotech, GL Biochem Ltd.
and Dr. Gogg Chemie AG. Tental Gel S RAM (loading:
0.25 mmol g1) were purchased fromRapp Polymere. Preparative
RP-HPLC was performed on a Waters PrepLC facility apparatus
using a Reprospher 100C-18-DE column, 5 mm, 100  30 mm
column. Eluent A: 0.1% TFA in 100% milliQ-H2O; eluent B: 50%
H2O, 50% MeCN; eluent C: 90% MeOH, 10% milliQ-H2O, 0.1%
TFA; eluent D: 90%MeCN, 10%milliQ-H2O, 0.1% TFA. Detection
with Waters 2489 UV Visible Detector at l ¼ 214 nm. MS spectra
were provided by Mass Spectrometry and Protein Analysis of the
Department of Chemistry and Biochemistry at the University of
Bern. Analytical UPLC was performed on Dionex Ultimate 3000
using an Acclaim RSLC 120 C18-column, 2.2 mm, 3.0  10 mm
eluent A: 0.1% TFA in 100% milliQ-H2O; eluent B: 50% milliQ-
H2O, 50% MeCN, eluent; C: 20% MeOH 80% milliQ-H2O 0.1%
TFA; eluent D: 90%MeCN, 10%milliQ-H2O, 0.1% TFA. Detection
by UV at l ¼ 214 nm. LC-MS data were collected aer coupling
the analytical system described above with a LCQ Fleet Ion Trap
mass spectrometer (Thermo Scientic, San Jose, CA, USA). LC-MS
data recording and processing was done with Xcalibur (version
2.2, Thermo Scientic).Cyclic peptides
All linear peptides were synthesized by solid phase peptide
synthesis (SPPS). The solid support was tentagel S RAM resin.
Synthesis of peptides was done manually in polypropylene7470 | Chem. Sci., 2017, 8, 7464–7475syringes. The resin was swelled in 7 mL DCM and the Fmoc
protecting groups were removed with 7 mL of solution of 20%
piperidine in DMF (2  20 min). For each coupling the amino
acid (3 eq.) and PyBOP (3 eq.) was dissolved in NMP (7 mL) and
added to the syringe. Then DIPEA (5 eq.) was added and the
reaction was stirred for 1 hour. Than the resin was washed 3
times with NMP (7 mL), MeOH (7 mL) and DCM (7 mL). The
Fmoc protecting groups were removed with 7 mL solution of
20% piperidine in DMF (2  20 min). The cleavage was carried
out with TFA/TIS/H2O (94 : 5:1) for 4.5 h and the peptide was
precipitated with methyl tert-butyl ether. The cyclization was
performed in high dilution in H2O/ACN, in presence of potas-
sium iodide and DIPEA. The cyclization was performed with
a,a0-dichloro-p-xylene (3 eq.), or a,a0-dichloro-o-xylene (3 eq.) or
a,a0-dichloro-m-xylene (3 eq.) as linkers for a double thioether
ligation and were monitored by LC-MS and were quenched aer
complete disappearance of the starting material (see ESI†). The
disulde-linked peptide was catalyzed with aldrithiol-2 in high
dilution in H2O with PH ¼ 7.8. The peptides were dissolved in
milli-Q H2O and puried by preparative HPLC to yield the TFA
salts aer lyophilization of the pooled pure fractions.Fucosylated cyclic peptides
The linear sequence was assembled by SPPS as described above
until removal of the last Fmoc group. Peracetylated a-L-fucosyl-
acetic acid (5 eq.), HATU (4 eq.) and DIPEA (10 eq.) were dis-
solved in 4.5 mL of NMP and 1.5 mL of DCM and added to the
syringe. The mixture was stirred overnight. The solvent
was ltrated followed by washing with NMP (2  6 mL), MeOH
(2  6 mL) and DCM (2  6 mL). Deacetylation when then
performed on solid support by stirring the resin for 24 h in
MeOH/H2O/NH3 (8 : 1 : 1). The resin was then ltered, washed,
and the TFA cleavage of the peptide, cyclization and nal HPLC
purication were performed as above.
RH6. Peptide RH6 was obtained as white solid aer prepara-
tive RP-HPLC purication (11.4 mg, 6.7%). Prep. RP-HPLC (A/D¼
100/0 to 0/100 in 60 min, 60mLmin1). Analytical RP-HPLC: tR¼
1.65 min (A/D ¼ 100/0 to 0/100 in 5 min, 1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.55,
found: 1711.42.
RH7. Peptide RH7 was obtained as white solid aer prepar-
ative RP-HPLC purication (17.5 mg, 9.5%). Prep. RP-HPLC
(A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analytical RP-
HPLC: tR ¼ 1.62 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C94H131N23O12S2 [M + H]
+: 1838.98,
found: 1838.58.
RH6m. Peptide RH6m was obtained as white solid aer
preparative RP-HPLC purication (8.7 mg, 5.1%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.70 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.15,
found: 1711.25.
RH6o. Peptide RH6o was obtained as white solid aer
preparative RP-HPLC purication (9.6 mg, 5.6%). Prep. RP-This journal is © The Royal Society of Chemistry 2017
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View Article OnlineHPLC (A/D¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analytical
RP-HPLC: tR ¼ 1.57 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.15,
found: 1711.33.
RH6ss. Peptide RH6ss was obtained as white solid aer
preparative RP-HPLC purication (17.5 mg, 10.9%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.75 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1). MS (ESI+) calculated for C80H111N21O11S2 [M +
H]+: 1607.01, found: 1607.58.
RH11. Peptide RH11 was obtained as white solid aer
preparative RP-HPLC purication (11.2 mg, 6.5%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.61 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.15,
found: 1711.25.
dRH11. Peptide dRH11 was obtained as white solid aer
preparative RP-HPLC purication (8.2 mg, 4.5%). Prep.
RP-HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1).
Analytical RP-HPLC: tR ¼ 1.62 min (A/D ¼ 100/0 to 0/100 in
5 min, 1.2 mL min1). MS (ESI+) calculated for C88H119N21O11S2
[M + H]+: 1711.15, found: 1711.17.
RH11o. Peptide RH11o was obtained as white solid aer
preparative RP-HPLC purication (8.1 mg, 4.7%). Prep.
RP-HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1).
Analytical RP-HPLC: tR ¼ 1.78 min (A/D ¼ 100/0 to 0/100 in
5 min, 1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.15,
found: 1711.67.
RH11m. Peptide RH11m was obtained as white solid aer
preparative RP-HPLC purication (9.1 mg, 5.2%). Prep.
RP-HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1).
Analytical RP-HPLC: tR ¼ 1.77 min (A/D ¼ 100/0 to 0/100 in
5 min, 1.2 mL min1).
MS (ESI+) calculated for C88H119N21O11S2 [M + H]
+: 1711.15,
found: 1711.75.
RH13. Peptide RH13 was obtained as white solid aer
preparative RP-HPLC purication (12.2 mg, 6.4%). Prep.
RP-HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1).
Analytical RP-HPLC: tR ¼ 1.79 min (A/D ¼ 100/0 to 0/100 in
5 min, 1.2 mL min1).
MS (ESI+) calculated for C99H129N23O12S2 [M + H]
+: 1897.36,
found: 1897.33.
dRH13. Peptide dRH13 was obtained as white solid aer
preparative RP-HPLC purication (6.1 mg, 3.4%). Prep.
RP-HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1).
Analytical RP-HPLC: tR ¼ 1.67 min (A/D ¼ 100/0 to 0/100 in
5 min, 1.2 mL min1). MS (ESI+) calculated for C99H129N23O12S2
[M + H]+: 1897.36, found: 1898.25.
RH14. Peptide RH14 was obtained as white solid aer
preparative RP-HPLC purication (10.5 mg, 5.9%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.71 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).This journal is © The Royal Society of Chemistry 2017MS (ESI+) calculated for C93H117N21O11S2 [M + H]
+: 1768.87,
found: 1768.25.
RH15. Peptide R15 was obtained as white solid aer
preparative RP-HPLC purication (14.8 mg, 9.0%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.51 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C83H121N21O11S2 [M + H]
+: 1652.90,
found: 1652.42.
RH17. Peptide RH17 was obtained as white solid aer
preparative RP-HPLC purication (19.6 mg, 11.5%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.61 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1). MS (ESI+) calculated for C88H119N21O11S2 [M +
H]+: 1711.15, found: 1711.67.
RH18. Peptide RH18 was obtained as white solid aer
preparative RP-HPLC purication (6.5 mg, 3.7%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.78 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1).
MS (ESI+) calculated for C90H123N21O11S2 [M + H]
+: 1739.20,
found: 1739.25.
RH19. Peptide RH19 was obtained as white solid aer
preparative RP-HPLC purication (3.6 mg, 2.1%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.91 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1). MS (ESI+) calculated for C90H123N21O11S2 [M +
H]+: 1738.9, found: 1739.58.
RH20. Peptide RH20 was obtained as white solid aer
preparative RP-HPLC purication (3.8 mg, 2.2%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 1.61 min (A/D ¼ 100/0 to 0/100 in 5 min,
1.2 mL min1). MS (ESI+) calculated for C90H123N21O11S2 [M +
H]+: 1738.9, found: 1739.58.
FRH11o. Peptide FRH11o was obtained as white solid aer
preparative RP-HPLC purication (8.3 mg, 4.8%). Prep. RP-
HPLC (A/D ¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analyt-
ical RP-HPLC: tR ¼ 3.88 min (A/D ¼ 100/0 to 0/100 in 10 min,
1.2 mL min1). MS (ESI+) calculated for C96H131N21O16S2 [M +
H]+: 1899.32, found: 1899.68.
FdRH11o. Peptide FdRH11o was obtained as white solid
aer preparative RP-HPLC purication (8.1 mg, 4.7%). Prep. RP-
HPLC (A/D¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analytical
RP-HPLC: tR ¼ 3.88 min (A/D ¼ 100/0 to 0/100 in 10 min,
1.2 mL min1). MS (ESI+) calculated for C96H131N21O16S2 [M +
H]+: 1899.32, found: 1899.68.
FdRH11m. Peptide FdRH11m was obtained as white solid
aer preparative RP-HPLC purication (5.9 mg, 3.4%). Prep. RP-
HPLC (A/D¼ 100/0 to 0/100 in 60 min, 60 mL min1). Analytical
RP-HPLC: tR ¼ 3.73 min (A/D ¼ 100/0 to 0/100 in 10 min,
1.2 mL min1). MS (ESI+) calculated for C96H131N21O16S2 [M +
H]+: 1899.32, found: 1899.63.Minimal inhibition concentration (MIC)
A colony of bacteria from glycerol stock was grown in Mu¨ller–
Hinton (MH) medium overnight at 37 C and 180 rpm shaking.Chem. Sci., 2017, 8, 7464–7475 | 7471
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View Article OnlineThe compounds were prepared as stock solutions of 8 mg mL1
in MH medium, added to the rst well of 96-well sterile, U-
bottomed polypropylene microtiter plates and diluted serially
by 1/2. Compounds containing solutions were sterile ltered
(pore size 0.22 mm) prior to addition to the wells. The concen-
tration of the bacteria was quantied bymeasuring absorbance at
600 nm and diluted to an OD600 of 0.022 in MH medium. The
sample solutions (150 mL) were mixed with 4 mL diluted bacterial
suspension with a nal inoculation of about 1  105 CFU. For
each test, two columns of the plate were kept for sterility control
(MH medium only), growth control (MH medium with bacterial
inoculum, no compound). Polymyxin B was used as a positive
control. The plates were incubated at 37 C for 18 hours. 15 mL
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (1 mg mL1 in sterilized milliQ deioinized water) were
added to each well and the plates were incubated for 10 minutes
at room temperature. The minimal inhibitory concentration
(MIC) was dened as the lowest concentration of the monocyclic
peptide that inhibits the visible growth of the tested bacteria
(yellow) with the unaided eye.
Minimal hemolytic concentration (MHC)
To determine the minimal hemolytic concentration (MHC)
stock solutions of 8 mg mL1 of the peptide in H2O were
prepared and 50 mL were diluted serially by 1/2 in 50 mL PBS (pH
7.4) in 96-well plate (Cornstar or Nunc, polystyrene, untreated).
Human red blood cells (hRBC) were obtained by centrifugation
of 1.5 mL of whole blood, from the blood bank of Bern, at
3000 rpm for 15 minutes at 4 C. Plasma was discarded and the
pellet was re-suspended in a 15 mL falcon tube up to 5 mL of
PBS. The washing was repeated three times and the remaining
pellet was re-suspended in 10 mL of PBS at a nal hRBC
concentration of 5%. The hRBC suspension (50 mL) was added
to each well and the plate was incubated at room temperature
for 4 hours. Minimal hemolytic concentration (MHC) end
points were determined by visual determination of the wells
aer the incubation period. Controls on each plate included
a blank medium control (50 mL PBS + 50 mL of hRBC suspen-
sion) and a hemolytic activity control (mQ-deionized water
50 mL + 50 mL hRBC suspension).
Serum stability assay
Human serum was diluted in DMEM (1 : 4, v/v). Selected
peptide was diluted in TRIS buﬀer to a concentration of
685 mg mL1. Aliquots of peptide solution (50 mL) were added to
aliquots of serum (50 uL) in sterile Eppendorf tubes, to reach
a peptide concentration of 200 mM during the assay. Samples
were incubated at 37 C under gentle stirring (350 rpm).
Diﬀerent samples (triplicates) were quenched at diﬀerent time
points (0/1/3/6/24 h) by precipitating serum proteins through
the addition of (0.1 M) ZnSO4  7H2O/ACN (1 : 1) (0.1 M,
100 mL) and cooling down in ice bath. Protein precipitates were
pelleted under centrifugation and the supernatants were
sampled and evaporated to dryness in a centrifugal evaporator.
Samples were re-suspended in a H2O/ACN (4 : 1, v/v) mixture
and centrifuged again to remove residual protein precipitate.7472 | Chem. Sci., 2017, 8, 7464–7475Supernatants were then sampled and analyzed by LC-MS.
Experiment controls included a precipitation control for each
peptide and serum blanks.
Kinetic assay
Kinetic assays were measured using a VARIAN, CARY Eclipse
Fluorescence Spectrophotometer. P. aeruginosa PA01 was incu-
bated overnight at 37 C and diluted with 60 mL MH medium
and incubated about 2 h to get an OD600 of 0.2–0.3. The bacteria
were split in 2, 50 mL sterile falcon tubes and centrifuged for
20 min at 5000 rpm at 4 C. Bacteria were washed with 45 mL
sterile 0.9% NaCl and centrifuged at 5000 rpm at 4 C. Bacteria
were diluted with sterile 0.9% NaCl to OD600¼ 0.1. The increase
of uorescence of 3 mL P. aeruginosa and 3 mL P. aeruginosa
with 3 mL of SYTOX (0.5 mM in DMSO) was measured as
references respectively at 37 C. To 3 mL P. aeruginosa PA01
treated with 3 mL SYTOX either 15 mL of polymyxin B
(1 mg mL1) or peptides to get a concentration of 4 MIC were
added to the cuvette. The addition of the peptides was at time
t ¼ 0. The experiments were measured with the following
parameters: 523 nm emission wavelength; 504 nm excitation
wavelength; 5 nm excitation slit, 5 nm emission slit; tempera-
ture control at 37 C and time control from 0 min to 120 min.
Transmission electron microscopy
Exponential phase of P. aeruginosa PAO1 were washed with PBS
and treated 10  MIC of the corresponding compound in M63
minimal medium. Each time, 1 mL of the bacteria were
centrifuged aer 15, 30 and 60 min at 12000 rpm for 3 min and
xed overnight with 2.5% glutaraldehyde in 0.15 M HEPES with
an osmolarity of 670 mOsm and adjusted to a pH of 7.35. The
next day, PAO1 were washed with 0.15 M HEPES three times for
5 min, post-xed with 1% OsO4 in 0.1 M Na-cacodylate-buﬀer at
4 C for 1 h. Thereaer, bacteria cells were washed in 0.1 M
maleate buﬀer three times for 5 min and dehydrated in 70, 80,
and 96% ethanol for 15 min each at room temperature.
Subsequently, they were immersed in 100% ethanol three times
for 10 min, in acetone two times for 10 min, and nally in
acetone–Epon (1 : 1) overnight at room temperature. The next
day, bacteria cells were embedded in Epon and hardened at
60 C for 5 days.
Sections were produced with an ultramicrotome UC6 (Leica
Microsystems, Vienna, Austria), rst semithin sections (1um)
for light microscopy which were stained with a solution of 0.5%
toluidine blue O and then ultrathin sections (70–80 nm) for
electron microscopy. The sections, mounted on single slot
copper grids, were stained with uranyl acetate and lead citrate
with an ultrostainer (Leica Microsystems, Vienna, Austria).
Sections were then examined with a Tecnai Spirit trans-
mission electron microscope equipped with two digital cameras
(Olympus-SIS Veleta CCD Camera, FEI Eagle CCD Camera).
Dynamic light scattering
Apparent particle sizes of the compounds and LPS solutions
and the mixtures were measured at 25 C by dynamic light
scattering (DLS) at 632.8 nm using a Malvern Zetasizer Nano ZSThis journal is © The Royal Society of Chemistry 2017
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View Article Online(Malvern, UK) and using original Ependorf disposable single
sealed Cuvettes, 50–2000 mL RNase-/DNA-/protein-free. LPS
(E. Coli, 0111:B4) aggregates and the compounds (polymyxin B,
tobramycin and RH11) were diluted to 200 mg mL1 in PBS. The
mixtures were prepared with a ratio of 1 : 1 of the LPS and the
compound of interest to reach a nal concentration of
100 mg mL1. As a control, LPS solution was diluted to
100 mg mL1 in PBS. The experiments were repeated three times.
Atomic force microscopy
AFM imaging was performed under ambient conditions in air
with a Nanosurf easyscan 2 (Nanosurf AG, Switzerland). All
measurements were carried out in tapping mode employing
PPP-NCHR-W cantilevers from Nanosensors (resonance
frequency  280 kHz, tip radius  10 nm). The mica substrates
(20  20 mm2) were attached to a steel baseplate with Scotch
tape and freshly cleaved prior to each new experiment. Peptides
at a concentration of 4 MIC were incubated with bacterial cell
(B. subtilis OD600 ¼ 0.1) in NaCl 0.9% for 10 min. The mixed
solution was deposited onto a freshly cleaved mica surface. The
solution was removed by gently rinsing with Milli-Q water aer
5 min of incubation time. Aer dried with Argon gas, the
substrate was analyzed with atom force microscopy. Peptide
without bacterial treatment and bacterial without peptides were
also analyzed by AFM as control. For details see ESI Fig. S2 and
S3.†
X-ray crystallography
LecB lectin was expressed, puried and dialyzed as previously
described.67 The crystals of the diﬀerent RH11 fucosylated
derivatives were carried out with the sitting drop method. In
brief, lyophilized protein was dissolved in water (5 mg mL1) in
the presence of salts (1 mM CaCl2 and MgCl2). The compounds
FdRH11o–LecB, FRH11o–LecB and FdRH11m–LecB were added
to the protein at a 20 : 1 molar excess, taking in to account, that
the biological unit of LecB is a homo-tetramer. Crystals were
obtained within ve days aer mixing 1.5 mL of LecB ligand-
complex with 1.5 mL of reservoir solution at 18 C. The best
diﬀracting crystals were found in the Index and Crystal screen of
Hampton research. In Detail, for FdRH11o–LecB, the best
condition was the condition F11 of the Index screen which
contains 0.005 M cadmium chloride hydrate, while for FRH11o–
LecB it was the Crystal screen F3 condition (0.5 M ammonium
sulfate, 0.1 M sodium citrate tribasic dehydrate, 1.0 M lithium
sulfate monohydrate, pH 5.6). Respectively for FdRH11m–LecB
it was the condition Index screen F4 (0.005 M cobalt(II) chloride
hexahydrate, 0.1 M HEPES, 12% polyethylene glycol 3350, pH
7.5). The structures were solved using the XDS,68 CCP4,69 the
phenix70 program suite and the coot71 graphical program.
Pictures were done with the help of pymol.72
Cheminformatics
The structures of all CAMPs analyzed were redrawn from the
original literature using ChemDraw, and exported as SMILES.
The combined SMILES le annotated with compound code and
antimicrobial activity data was then imported into WebMolCSThis journal is © The Royal Society of Chemistry 2017to visualize the spread of structural features in various
3D-chemical spaces.73 The key parameters identied by this
analysis (net charge vs. size and aromatic carbon versus non-
aromatic carbons) were then extracted from the correspond-
ing descriptor analysis and replotted in Fig. S7A and B.†Conﬂicts of interest
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